Invention Summary:
Hydrogel-based wound dressing is an accepted clinical practice for the promotion of wound healing and/or drug delivery. However, current hydrogel-based technologies have disadvantages including difficulty in removal, prone to gelling during packaging or storage, and requiring temperature manipulation before administration.
Rutgers scientists have developed a novel and easy to use hydrogel wound dressing that gels in-situ immediately upon the mixture of two solution systems. This hydrogel can be administered by a spray and has a unique feature of reversibility, which enables an easy and painless removal of the dressing. Because of this feature, this hydrogel system is also an optimum choice for wound dressing, drug delivery carrier, including ocular application of therapeutics, providing a highly comfortable user experience. In addition, RGD peptide system which is known to bind to multiple cell surface integrin species, can be added for drug conjugation, allowing controlled drug release, increased cell adhesion capability, and prolonged residence time for drugs at administered sites, such as corneal surface or skin.
This hydrogel technology is extremely versatile with applications ranging from covering wounds, to a topical or transdermal delivery of drugs, such as doxycycline, lidocaine, olvanil, pilocarpine, etc.
Market Applications:
- Wound care and wound healing
- Topical or ocular drug delivery system
Advantages:
- Stable and easy-to-use spray-on hydrogel
- Reversible crosslinking capability allowing stress-free removal
- Biodegradable and eco-friendly
- Comfortable wearing experience
- Non-toxic
Intellectual Property & Development Status:
Issued patent and a pending patent application. Available for licensing and/or research collaboration.
